Ten years of HPV vaccines: State of art and controversies

Critical Reviews in Oncology/Hematology

Volumn 102, Issue , 2016, Pages 65-72

  Angioli, Roberto ^a   Lopez, Salvatore ^a   Aloisi, Alessia ^a   Terranova, Corrado ^a   De Cicco, Carlo ^a   Scaletta, Giuseppe ^a   Capriglione, Stella ^a   Miranda, Andrea ^a   Luvero, Daniela ^a   Ricciardi, Roberto ^a   Montera, Roberto ^a,b   Plotti, Francesco ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Bivalent; HPV; Ninevalent; Quadrivalent; Vaccine

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER PREVENTION; CONDYLOMA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INFECTION PREVENTION; MULTICENTER STUDY (TOPIC); PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION REACTION; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVA TUMOR; VULVAR INTRAEPITHELIAL NEOPLASIA; COMPLICATION; FEMALE; PAPILLOMAVIRUS INFECTIONS; PRECANCER; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84962658968     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2016.03.020     Document Type: Review

References (66)

1. Bellone S., El-Sahwi K., Cocco E., Casagrande F., Cargnelutti M., Palmieri M., et al. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines. J. Virol. 2009, 83:6779-6789.
2. Bhatla N., Suri V., Basu P., Shastri S., Datta S.K., Bi D., et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J. Obstet. Gynaecol. Res. 2010, 36:123-132.
3. Binagwaho A., Wagner C.M., Gatera M., Karema C., Nutt C.T., Ngabo F. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull. World Health Organ. 2012, 90:623-628.
4. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 2002, 55:244-265.
5. Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., de Sanjose S., Bruni L., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl. 10):K1-16.
6. Burd E.M. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 2003, 16:1-17.
7. Centers for Disease C, Prevention. Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013-United States. MMWR Morbidity and mortality weekly report. 2013;62:591-5.
8. Cogliano V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005, 6:204.
9. Dillner J., Arbyn M., Unger E., Dillner L. Monitoring of human papillomavirus vaccination. Clin. Exp. Immunol. 2011, 163:17-25.
10. Draper E., Bissett S.L., Howell-Jones R., Waight P., Soldan K., Jit M., et al. A randomized, observer-blinded immunogenicity trial of Cervarix((R)) and Gardasil((R)) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One 2013, 8:e61825.
11. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136:E359-86.
12. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007, 356:1928-1943.
13. Gee J., Naleway A., Shui I., Baggs J., Yin R., Li R., et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011, 29:8279-8284.
14. Group F.I.I.S., Dillner J., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493.
15. Group F.I.S. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 2007, 356:1915-1927.
16. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
17. Haupt R.M., Wheeler C.M., Brown D.R., Garland S.M., Ferris D.G., Paavonen J.A., et al. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int. J. Cancer 2011, 129:2632-2642.
18. Herrero R., Hildesheim A., Rodriguez A.C., Wacholder S., Bratti C., Solomon D., et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008, 26:4795-4808.
19. Herrero R., Gonzalez P., Markowitz L.E. Present status of human papillomavirus vaccine development and implementation. Lancet Oncol. 2015, 16:e206-e216.
20. Hildesheim A., Wacholder S., Catteau G., Struyf F., Dubin G., Herrero R., et al. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine 2014, 32:5087-5097.
21. Joura E.A., Ault K.A., Bosch F.X., Brown D., Cuzick J., Ferris D., et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol. Biomarkers Prev. 2014, 23:1997-2008.
22. Joura E.A., Giuliano A.R., Iversen O.E., Bouchard C., Mao C., Mehlsen J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 2015, 372:711-723.
23. Kang S., Kim K.H., Kim Y.T., Kim Y.T., Kim J.H., Song Y.S., et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Int. J. Gynecol. Cancer 2008, 18:1013-1019.
24. Kim Y.J., Kim K.T., Kim J.H., Cha S.D., Kim J.W., Bae D.S., et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. J. Korean Med. Sci. 2010, 25:1197-1204.
25. Kim S.C., Song Y.S., Kim Y.T., Kim Y.T., Ryu K.S., Gunapalaiah B., et al. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women. J. Gynecol. Oncol. 2011, 22:67-75.
26. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:12180-12184.
27. Kreimer A.R., Gonzalez P., Katki H.A., Porras C., Schiffman M., Rodriguez A.C., et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol. 2011, 12:862-870.
28. Kreimer A.R., Struyf F., Del Rosario-Raymundo M.R., Hildesheim A., Skinner S.R., Wacholder S., et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015.
29. Lazcano-Ponce E., Perez G., Cruz-Valdez A., Zamilpa L., Aranda-Flores C., Hernandez-Nevarez P., et al. Impact of a quadrivalent HPV6/11/16/18 vaccine in Mexican women: public health implications for the region. Arch. Med. Res. 2009, 40:514-524.
30. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012, 13:89-99.
31. Ling W.Y., Razali S.M., Ren C.K., Omar S.Z. Does the success of a school-based HPV vaccine programme depend on teachers' knowledge and religion?-A survey in a multicultural society. Asian Pac. J. Cancer Prev. 2012, 13:4651-4654.
32. Macartney K.K., Chiu C., Georgousakis M., Brotherton J.M. Safety of human papillomavirus vaccines: a review. Drug Saf. 2013, 36:393-412.
33. Medina D.M., Valencia A., de Velasquez A., Huang L.M., Prymula R., Garcia-Sicilia J., et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J. Adolesc. Health 2010, 46:414-421.
34. Monie A., Hung C.F., Roden R., Wu T.C. Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics 2008, 2:97-105.
35. Moscicki A.B., Ma Y., Wibbelsman C., Darragh T.M., Powers A., Farhat S., et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet. Gynecol. 2010, 116:1373-1380.
36. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. Med. 2003, 348:518-527.
37. Munoz N., Bosch F.X., Castellsague X., Diaz M., de Sanjose S., Hammouda D., et al. Against which human papillomavirus types shall we vaccinate and screen: The international perspective. Int. J. Cancer 2004, 111:278-285.
38. Munoz N., Castellsague X., de Gonzalez A.B., Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24(Suppl. 3). (S3/1-10).
39. Munoz N., Manalastas R., Pitisuttithum P., Tresukosol D., Monsonego J., Ault K., et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009, 373:1949-1957.
40. Naud P.S., Roteli-Martins C.M., De Carvalho N.S., Teixeira J.C., de Borba P.C., Sanchez N., et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum. Vaccines Immunother. 2014, 10:2147-2162.
41. Ngan H.Y., Cheung A.N., Tam K.F., Chan K.K., Tang H.W., Bi D., et al. Human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med. J. 2010, 16:171-179.
42. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
43. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
44. Pagliusi S.R., Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004, 23:569-578.
45. Palefsky J.M., Giuliano A.R., Goldstone S., Moreira E.D., Aranda C., Jessen H., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 2011, 365:1576-1585.
46. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl. 3). S3/11-25.
47. Petrosky E., Bocchini J.A., Hariri S., Chesson H., Curtis C.R., Saraiya M., et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb. Mortal. Wkly. Rep. 2015, 64:300-304.
48. Rambout L., Hopkins L., Hutton B., Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007, 177:469-479.
49. Roden R.B., Ling M., Wu T.C. Vaccination to prevent and treat cervical cancer. Hum. Pathol. 2004, 35:971-982.
50. Santin A.D., Bellone S., Gokden M., Cannon M.J., Parham G.P. Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N. Engl. J. Med. 2002, 346:1752-1753.
51. Santin A.D., Bellone S., Palmieri M., Zanolini A., Ravaggi A., Siegel E.R., et al. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J. Virol. 2008, 82:1968-1979.
52. Schiller J.T., Castellsague X., Villa L.L., Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl. 10):K53-61.
53. Serrano B., Alemany L., Tous S., Bruni L., Clifford G.M., Weiss T., et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect. Agents Cancer 2012, 7:38.
54. Shi L., Sings H.L., Bryan J.T., Wang B., Wang Y., Mach H., et al. GARDASIL: prophylactic human papillomavirus vaccine development-from bench top to bed-side. Clin. Pharmacol. Ther. 2007, 81:259-264.
55. Stanley M. HPV-immune response to infection and vaccination. Infect. Agents Cancer 2010, 5:19.
56. Stillo M., Carrillo Santisteve P., Lopalco P.L. Safety of human papillomavirus vaccines: a review. Expert Opin. Drug Saf. 2015, 14:697-712.
57. Tjalma W.A., Fiander A., Reich O., Powell N., Nowakowski A.M., Kirschner B., et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int. J. Cancer 2013, 132:854-867.
58. Tota J.E., Ramanakumar A.V., Jiang M., Dillner J., Walter S.D., Kaufman J.S., et al. Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination. Am. J. Epidemiol. 2013, 178:625-634.
59. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 2006, 24:5571-5583.
60. WHO Human papillomavirus vaccines: WHO position paper. Biologicals 2009, 37:338-344.
61. Wacholder S., Chen B.E., Wilcox A., Macones G., Gonzalez P., Befano B., et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ 2010, 340:c712.
62. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
63. Zhou J., Sun X.Y., Stenzel D.J., Frazer I.H. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 1991, 185:251-257.
64. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11:1048-1056.
65. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., zur Hausen H. Classification of papillomaviruses. Virology 2004, 324:17-27.
66. zur Hausen H. Human papillomaviruses and their possible role in squamous cell carcinomas. Curr. Top. Microbiol. Immunol. 1977, 78:1-30.